Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported Q1 2026 net product sales of $159.9 million and raised 2026 net product sales guidance to $660–$680 million. LIVMARLI sales were $113.8 million (+55% YoY); Bile Acid Medicines sales were $46.1 million (+20% YoY). Clinical updates: volixibat VISTAS and brelovitug AZURE-1 Phase 2b met primary endpoints. Mirum licensed zilurgisertib for FOP; the FDA accepted the NDA and granted Priority Review with a PDUFA date of Sept 26, 2026. Q1 operating expenses included a $726.3 million non-recurring IPR&D charge; cash, cash equivalents, and investments were $420.6 million as of March 31, 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that the VISTAS Phase 2b study of volixibat in primary sclerosing cholangitis met its primary endpoint. In the primary cohort (n=111) volixibat showed an LS mean itch change of -2.72 versus -1.08 for placebo; placebo-adjusted difference -1.64 (p<0.0001). Secondary signals included ≥2-point responder rate 55.6% vs 26.3% (difference 29.3%, p=0.0019) and sBA reduction. Safety showed more GI events, liver lab elevations, and higher discontinuations with volixibat. A pre-NDA meeting with FDA is scheduled for summer 2026 and an NDA filing is planned in H2 2026; full results will be presented May 30 at EASL.
Mirum Pharmaceuticals (Nasdaq: MIRM) will host an investor call on May 4, 2026 at 8:30 a.m. ET / 5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC).
Access is by US toll-free and international phone numbers or via webcast on the company Investors website; an archived replay will be available.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report first quarter 2026 financial results and host a conference call on May 6, 2026 at 4:30 p.m. ET / 1:30 p.m. PT.
Dial-in numbers and an international line are provided; a live webcast and archived replay will be available via the Investors section of Mirum's website.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that the Phase 2b portion of AZURE-1 met its primary composite endpoint at Week 24 for brelovitug in chronic hepatitis delta virus (HDV).
At Week 24, virologic response occurred in 100% (300 mg QW) and 75% (900 mg Q4W) versus 0% delayed; composite endpoint achieved in 45% and 35% versus 0%. Safety was described as favorable. Full Phase 2b results will be presented at EASL May 27-30, 2026; Phase 3 toplines expected H2 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement grants on April 10, 2026: non-qualified stock options to purchase 13,700 shares and 18,200 restricted stock units issued to 12 new employees under the 2020 Inducement Plan.
Each option has an exercise price of $95.20 (closing price on April 10, 2026). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over three years (33% each anniversary). Awards are subject to plan and award agreement terms.
Mirum Pharmaceuticals (Nasdaq: MIRM) completed enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI (maralixibat) for cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia.
The 20-week placebo-controlled portion randomizes patients to maralixibat 285 µg/kg twice daily or placebo; the primary endpoint is change in pruritus severity to Week 20. Topline data expected Q4 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported inducement grants on March 11, 2026 under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted non-qualified stock options to purchase 5,400 shares and 6,800 RSUs to five new employees.
Options carry an exercise price of $91.75 (Mirum closing price on March 11, 2026). Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years (33% each anniversary). Awards are governed by Mirum’s 2020 Inducement Plan and award agreements, and are conditioned on continued service.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported completion of enrollment in Phase 3 AZURE-1 and completion of screening in Phase 3 AZURE-4 for brelovitug in chronic hepatitis delta virus (HDV).
Topline 24-week results from both studies are expected in 2H 2026; AZURE-1 and AZURE-4 will form the basis of a U.S. BLA filing with a potential U.S. launch in 2027. Brelovitug holds Breakthrough Therapy designation from the FDA.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported 2025 net product sales of $521.3M and provided 2026 guidance of $630M–$650M in expected global net product sales. The company highlighted multiple near‑term registrational readouts in 2026 and recent regulatory approvals and an acquisition expanding its HDV program.
Key near‑term catalysts include VISTAS topline in PSC (Q2 2026), LIVMARLI EXPAND topline (Q4 2026), and AZURE HDV readouts in H2 2026. Cash and investments were $391.4M at year‑end 2025.